VASCULAR

VBLT NASDAQ
1.220
-0.030
-2.40%
Closed 16:00 06/20 EDT
Open
1.250
Prev Close
1.250
High
1.250
Low
1.220
Volume
3.63K
Avg Vol (3M)
94.03K
52 Week High
2.800
52 Week Low
0.6000
% Turnover
0.01%
Market Cap
43.77M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers VASCULAR VBLT stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company's program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels. Its lead product candidate, VB-111(ofranergene obadenovec), is a gene-based biologic that it is developing for solid tumor indications, with a program for recurrent glioblastoma (rGBM), a form of brain cancer. It also is engaged in conducting a program focusing anti-inflammatory diseases, based on the use of its Lecinoxoid platform technology. Lecinoxoids are a class of small molecules it developed that are structurally and functionally similar to naturally occurring molecules known to modulate inflammation. The lead product candidate from this program, VB-201, is a Phase II-ready molecule.
MORE >

Recently

Name
Price
%Change